Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: The National Health Commission said on Monday that 78 new asymptomatic cases had been identified as of the end of Sunday, compared with 47 the day before. Imported cases and asymptomatic patients, who show no symptoms but can still pass the virus on, have become China's chief concern after draconian containment measures succeeded in slashing the overall infection rate. Hubei province, the original epicentre, accounted for almost half the new asymptomatic cases. A total of 705 people with asymptomatic cases were under medical observation around mainland China. The surge in asymptomatic cases, which China only began reporting last week, poses a worry as Hubei's capital Wuhan prepares to allow people to leave the city on April 8 for the first time since it was locked down in late January. Wuhan officials revoked the "epidemic-free" status of 45 residential compounds due to the emergence of asymptomatic cases and other unspecified reasons, according to a report on Monday by the official Xinhua news agency. "Epidemic-free" status allows people living in Wuhan compounds to leave their homes for two hours at a time. China has now reported a total of 81,708 cases, with 3,331 deaths. One new locally transmitted infection was reported in the latest data, in the southern province of Guangdong, down from five a day earlier in the same province. China has closed its borders to foreigners as the virus spreads globally, though most imported cases have involved Chinese nationals returning from overseas. It began testing all international arrivals for the coronavirus from April 1, customs official Song Yueqian said. Of the new cases showing symptoms, 38 entered China from abroad, compared with 25 a day earlier. Of those, 20 arrived in the northeastern province of Heilongjiang from neighbouring Russia. All were Chinese citizens who had flown from Moscow to Vladivostok and travelled to China overland. China will work to prevent cases being imported through land borders, the government said after a meeting chaired by Premier Li Keqiang on Monday,which noted the number of such cases had exceeded cases recorded at airports recently. Those who try to hide their travel history or health condition face a fine of up to 30,000 yuan ($4,230) or even criminal proceedings, Song said, adding such people will be placed on a customs "blacklist" of travellers who will be subject to tighter checks in future. Another possible source of infection are the 1.6 million Chinese who study overseas, many of whom have struggled to return home since international flights were reduced. Charter flights are being arranged to bring home Chinese students in the United States, starting with the youngest, China's embassy in Washington said. The ambassador, Cui Tiankai, noted in the New York Times on Monday there had been "unpleasant talk" between the two countries about the virus. "But this is not the time for finger-pointing. This is a time for solidarity, collaboration and mutual support," Cui wrote. Amid criticism China was too slow to warn the international community about the outbreak, Xinhua on Monday published a "detailed timeline" of the country's coronavirus response and information sharing, from late December 2019 to March 2020. China started reporting to the United States "regularly" on the epidemic and containment measures from Jan. 3, according to the timeline. Click here for an interactive GRAPHIC tracking global spread of coronavirus

Output: China sees rise in asymptomatic coronavirus cases, to tighten controls at land borders.

Input: Consider Input: Teva Pharmaceutical Industries Ltd's rival migraine headache preventer is excluded on one list and patients can pay more for it in some cases on a second list, the note said. As with rival PBMs Express Scripts and CVS Health Corp, OptumRx's lists of covered drugs, or formularies, cover tens of millions of consumers who receive their healthcare from employers and health insurers. About 39 million Americans suffer from migraine headaches, according to the Migraine Research Foundation, and global migraine drug sales could reach $8.7 billion by 2026, according to analytics firm GlobalData. OptumRx's decision secures easier access to customers for Lilly's Emgality at all three of the biggest PBMs - including CVS and Express Scripts - and gives Amgen's Aimovig a leg up after CVS decided not to include it on its preferred drug list. Teva's Ajovy only has preferred status at CVS, while Amgen also has it at Express Scripts, part of Cigna Corp. "We are pleased that all three companies have chosen Emgality to be one of the preferred medications, making it accessible to even more patients suffering from migraine," Lilly said in an emailed statement. Inclusion on a preferred drugs list by the largest PBMs and health insurers is critically important for sales of new medicines. Increasingly, PBMs are choosing a subset of treatments for their coverage list when there are multiple treatments that are considered equivalent. The three treatments, approved by the U.S. Food and Drug Administration last year, belong to a class of drugs called CGRP inhibitors that have proven effective in helping to prevent migraines. A Teva spokeswoman said the company is committed to increasing access to Ajovy regardless of formulary decisions and is still offering discounts that allow patients to pay nothing in some cases, regardless of insurance. "Since Ajovy injection launched in September, we have experienced strong demand and steady growth, and we continue discussions with payers," the spokeswoman said. An Amgen spokeswoman said that the company was pleased with the decision and is committed to ensuring affordable access to its drug. Amgen, which shares Aimovig U.S. revenue with Novartis AG, earlier this week reported fourth-quarter sales of $95 million, nearly doubling Wall Street estimates. The OptumRx decision becomes effective Feb. 1. The OptumRx select formulary relegates Teva's drug to a lower access level that would typically require a higher out-of-pocket cost, it said. PBMs typically extract discounts from drugmakers in return for favorable placement on their preferred list of covered drugs, such as through a low co-payment, or coinsurance payment, for their members. All three migraine drugs have a list price of $575 a month, or $6,900 a year. Those prices do not reflect the rebates and discounts to PBMs, who design and negotiate benefits for employers and insurers. All three drugmakers are providing a limited duration supply of the new drugs at no cost directly to patients in addition to other assistance programs. Amgen's Aimovig was first-to-market from the new class. But the rivals from Teva and Lilly followed soon after. The three large PBMs together cover the majority of the more than 150 million Americans who receive benefits through their employers. Their clients, including insurers and corporations, may choose not to follow a PBM's recommendations on coverage, but that typically would cost more. Amgen shares were off 28 cents at $186.63, Lilly was up nearly 1 percent at $120.90 and Teva shares traded in New York were down nearly 1 percent at $19.69.

Output: Exclusive: Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva.

Input: Consider Input: The accord announced on Thursday by the U.S. Department of Justice resolves allegations that CareFusion violated the federal False Claims Act by paying $11.6 million to a doctor to promote its ChloraPrep product to healthcare providers. That doctor, Charles Denham, received the kickbacks while serving as co-chair of the safe practices committee of the nonprofit National Quality Forum, which makes recommendations on healthcare practices, the Justice Department said. "Corrupting the standard-setting process through kickbacks can affect the healthcare treatment choices that doctors and hospitals may make for patients," Stuart Delery, assistant attorney general for the Justice Department's civil division, said in a statement. The lawsuit also claimed that CareFusion promoted ChloraPrep from September 2009 through August 2011 for unapproved uses. The U.S. Food and Drug Administration had approved ChloraPrep to prepare patients' skin for surgery or injections. CareFusion said on Thursday that it set aside funds for the settlement in the first quarter of 2013. Chief Executive Officer Kieran Gallahue said the San Diego-based company is pleased to settle, and has made "significant investments" to improve its quality and compliance practices, including in sales and marketing. Denham could not immediately be reached for comment. The accord resolved a whistleblower lawsuit first brought in September 2010 by Cynthia Kirk, a former vice president of regulatory affairs at a CareFusion infection prevention unit. She will receive $3.26 million through the settlement, which along with the lawsuit was unsealed this week by the federal court in Kansas City, Kansas. In afternoon trading, CareFusion shares were up 81 cents at $41.12. The case is U.S. ex rel. Kirk v. CareFusion Corp et al, U.S. District Court, District of Kansas, No. 10-02492.
Output: CareFusion to pay $40 million to settle U.S. kickbacks lawsuit.